The incubator anchored at the company's global headquarters in Raleighla launches alongside an inaugural partnership with Cape Fear BioCapital, a Durham-based seed-stage venture capital firm
Suven has already begun planning a global Phase 3 registrational program for MDD based on the results
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
The decision was driven by results from the Phase III CAPItello-281 trial,
The regulatory decision follows promising results from RIVER-81
KIHT can now conduct clinical research for drugs and medical devices, strengthening evidence generation and healthcare innovation
Company experts to participate in eight sessions covering AI-powered clinical development, regulatory innovation, oncology research, and patient engagement
The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
New PARTNER trial sub-study data show that post-operative ctDNA detection using tumour-informed MRD assays can accurately predict distant recurrence risk in triple-negative breast cancer patients
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
The safety profile was described as manageable, though not without notable toxicities
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
While overall survival data remain immature, the results pointed to a favourable trend.
The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival
This marks one of the most closely watched oncology readouts at this year’s medical congress
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
